Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial von Mickisch, GHJ, Garin, A, van Poppel, H, de Prijck, L, Sylvester, R

Volltext

Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib von Mickisch, G, Gore, M, Escudier, B, Procopio, G, Walzer, S, Nuijten, M

Volltext

A multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN von Melichar, B., Bracarda, S., Matveev, V., Alekseev, B., Ivanov, S., Zyryanov, A., Janciauskiene, R., Fernebro, E., Mulders, P., Osborne, S., Jethwa, S., Mickisch, G., Gore, M., van Moorselaar, R.J.A., Staehler, M., Magne, N., Bellmunt, J.

Volltext

Assessing the impact of evolving evidence in renal cell carcinoma treatment: An update of the Renal Cell Carcinoma Appropriateness-based Treatment Toolkit (ReCATT) von Gore, M.E, Bellmunt, J, Eisen, T, Escudier, B, Mickisch, G, Patard, J, Porta, C, Ravaud, A, Schmidinger, M, Schöffski, P, Sternberg, C.N, Szczylik, C, Lewis, S, Kirpekar, S

Volltext

Rational Selection of a Control Arm for Randomised Trials in Metastatic Renal Cell Carcinoma von Mickisch, G.H.J.

Volltext

Principles of nephrectomy for malignant disease von Mickisch, G.H.J.

Volltext

A phase II trial of methotrexate-human serum albumin (MTX-HSA) in patients with metastatic renal cell carcinoma who progressed under immunotherapy von VIS, A. N, VAN DER GAAST, A, VAN RHIJN, B. W. G, CATSBURG, T. K, SCHMIDT, C, MICKISCH, G. H. J

Volltext

Evaluation of treatment options for patients with advanced renal cell carcinoma: Assessment of appropriateness, using the validated semi-quantitative RAND corporation/University of... von Gore, M.E, Bellmunt, J, Eisen, T, Escudier, B, Mickisch, G, Patard, J, Porta, C, Ravaud, A, Schmidinger, M, Schöffski, P, Sternberg, C.N, Szczylik, C, De Nigris, E, Wheeler, C, Kirpekar, S

Volltext

Reply: Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib von Mickisch, G H J, Escudier, B, Walzer, S, Nuijten, M

Volltext

Chemosensitivity of prostate cancer cell lines and expression of multidrug resistance-related proteins von van Brussel, J.P, van Steenbrugge, G.J, Romijn, J.C, Schröder, F.H, Mickisch, G.H.J

Volltext

Identification of multidrug resistance‐associated protein 1 and glutathione as multidrug resistance mechanisms in human prostate cancer cells: chemosensitization with leukotriene D... von Van Brussel, J.P., Oomen, M.A., Vossebeld, P.J.M., Wiemer, E.A.C., Sonneveld, P., Mickisch, G.H.J.

Volltext

Transgenic Mice that Express the Human Multidrug-Resistance Gene in Bone Marrow Enable a Rapid Identification of Agents that Reverse Drug Resistance von Mickisch, Gerald H., Merlino, Glenn T., Galski, Hanan, Gottesman, Michael M., Pastan, Ira

Volltext

7114 POSTER DISCUSSION Appropriateness of Treatment Options for the Management of Patients With Advanced Renal Cell Carcinoma (RCC) Using the Validated Semi Quantitative RAND Corpo... von Gore, M, Bellmunt, J, Eisen, T, Mickisch, G, Patard, J, Porta, C, Ravaud, A, Schmidinger, M, Sternberg, C, Szczylik, C, De Nigris, E, Kirpekar, S, Wheeler, C

Volltext

Prognostic factors in renal cell and bladder cancer von Van Brussel, J P, Mickisch, G H

Volltext

Erratum: Letter to the Editor: SUN vs BEVþIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival von Nuijten, M, Mickisch, G

Volltext

Letter to the Editor: SUN vs BEVþIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival von Nuijten, M, Mickisch, G

Volltext

SUN vs BEVþIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival von Nuijten, M, Mickisch, G

Volltext

The European Medicines Agency Approval of Axitinib (Inlyta) for the Treatment of Advanced Renal Cell Carcinoma After Failure of Prior Treatment With Sunitinib or a Cytokine: Summar... von Tzogani, Kyriaki, Skibeli, Venke, Westgaard, Ingunn, Dalhus, Marianne, Thoresen, Hege, Slot, Karsten Bruins, Damkier, Per, Hofland, Kenneth, Borregaard, Jeanett, Ersbøll, Jens, Salmonson, Tomas, Pieters, Ronny, Sylvester, Richard, Mickisch, Gerald, Bergh, Jonas, Pignatti, Francesco

Volltext

Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate can... von ALBRECH, W, VAN POPPEL, H, SYLVESTER, R, HORENBLAS, S, MICKISCH, G, HORWICH, A, SERRETTA, V, CASETTA, G, MARECHAL, J. M, JONES, W. G, KALMAN, S

Volltext

Chemoresistance of renal cell carcinoma: 1986-1994 von MICKISCH, G. H

Volltext